Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Anteris Technologies GlobalASX:AVR +1.48%50 Days Sales Outstanding is 35.24 as of Jun. 2026, which is 14% below its 10-year median of 41.14. GuruFocus rates ASX:AVR with a GF Score™ of 50/100. The stock has 5 warning signs investors should review. Among 810 Medical Devices & Instruments companies, Anteris Technologies Global ranks better than 61.36% on this metric.
The historical rank and industry rank for Anteris Technologies Global's Days Sales Outstanding or its related term are showing as below:
ASX:AVR'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 22.9 Med: 41.14 Max: 56.39
Current: 56.39
During the past 13 years, Anteris Technologies Global's highest Days Sales Outstanding was 56.39. The lowest was 22.90. And the median was 41.14.
ASX:AVR's Days Sales Outstanding is ranked better than 61.36% of 810
companies
in the Medical Devices & Instruments industry
Industry Median: 65.21
vs ASX:AVR: 56.39
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anteris Technologies Global Days Sales Outstanding Chart
ASX:AVR vs BVS, SIBN, INMD: Days Sales Outstanding Comparison
For the Medical Devices subindustry, Anteris Technologies Global's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anteris Technologies Global Days Sales Outstanding vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Anteris Technologies Global's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Anteris Technologies Global's Days Sales Outstanding falls into.
Anteris Technologies Global Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anteris Technologies Global (ASX:AVR) has a Days Sales Outstanding of 35.24 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Anteris Technologies Global and its competitors. This is 14% below median its historical median of 41.14. Over the past decade, Anteris Technologies Global's Days Sales Outstanding has ranged from 22.90 to 56.39. According to the industry distribution chart, Anteris Technologies Global ranks #313 out of 810 companies in the Medical Devices & Instruments industry, placing it in the top 38.6%.
Is Anteris Technologies Global's Days Sales Outstanding too high?
Anteris Technologies Global's current Days Sales Outstanding of 35.24 is 14% below median its 10-year median of 41.14. Over the past 10 years, this metric has ranged from a low of 22.90 to a high of 56.39. The Medical Devices & Instruments industry median Days Sales Outstanding is 65.21. Anteris Technologies Global's value of 35.24 is 46% below this industry median. Based on the distribution chart, Anteris Technologies Global ranks #313 out of 810 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Anteris Technologies Global has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does Anteris Technologies Global's Days Sales Outstanding compare to BVS and SIBN?
According to the Medical Devices & Instruments industry distribution chart, Anteris Technologies Global ranks #313 out of 810 companies for Days Sales Outstanding. This puts Anteris Technologies Global in the upper half of its industry. The industry median Days Sales Outstanding is 65.21. Anteris Technologies Global's value of 35.24 is 46% below this benchmark. Historically, Anteris Technologies Global's own Days Sales Outstanding has ranged from 22.90 to 56.39 over the past decade. While the company's 10-year median is 41.14 vs. the industry median of 65.21, Anteris Technologies Global has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Medical Devices & Instruments company?
The median Days Sales Outstanding among Medical Devices & Instruments companies is 65.21, based on 810 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Anteris Technologies Global's current Days Sales Outstanding of 35.24 is 46% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Anteris Technologies Global and its competitors. For the Medical Devices & Instruments industry, the median Days Sales Outstanding is 65.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anteris Technologies Global's current Days Sales Outstanding is 35.24, which is 14% below median its own 10-year median of 41.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anteris Technologies Global stock overvalued right now?
Anteris Technologies Global (ASX:AVR) has a current Days Sales Outstanding of 35.24. The current Days Sales Outstanding is 35.24, which is 14% below median its 10-year median of 41.14 and 46% below the Medical Devices & Instruments industry median of 65.21. Anteris Technologies Global's overall GF Score™ is 50/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Anteris Technologies Global (ASX:AVR), the current Days Sales Outstanding is 35.24 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anteris Technologies Global Corp is a structural heart company focused on advancing cardiac care through science-driven innovations aimed at restoring heart valve patients to healthy function. Its key product, the DurAVR Transcatheter Heart Valve (THV), was designed in partnership with interventional cardiologists and cardiac surgeons to treat Aortic Stenosis, a potentially life-threatening condition caused by narrowing of the aortic valve. The balloon-expandable DurAVR THV is a biomimetic valve designed to mimic the performance of a healthy human aortic valve and replicate normal aortic blood flow. The company operates in United States, Germany, Australia, Switzerland, and Sweden, with the majority of its revenue generated from the United States.
50GF Score
Get the complete analysis for ASX:AVR
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:AVR has been successfully added to your 
